Genscript Biotech (HK:1548) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Genscript Biotech Corporation has exercised its conversion rights to convert $70 million in convertible bonds into 106 million ordinary shares of its subsidiary, Probio Cayman. This move increases Genscript’s ownership in Probio Cayman to approximately 71.72%, enhancing its influence in the subsidiary. Investors are advised to be cautious as they evaluate the implications of this strategic financial decision.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
